-
Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment
•
Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and Suzhou, China, has reportedly raised tens of millions of renminbi in its latest financing round, co-led by Hidea Investment. Company BackgroundFounded in 2015, Curatia specializes in biomaterials, machinery, coatings, metal weaving, extrusion, abrasives, and other…
-
Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang
•
China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy Chain Co., Ltd, will establish a new company with Tangshan Deshuntang Pharmaceutical Chain Co., Ltd. The new entity, tentatively named Tangshan Xinxing Deshuntang Pharmaceutical Chain Co., Ltd, will take over all business and assets of…
-
Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue 128,144,927 A shares at RMB 42 (USD 6.20) per share. The proceeds, totaling RMB 4.48 billion (USD 662 million), will be allocated to clinical studies of novel drugs, licensing deals, product launches, and the construction…
-
MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines
•
MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9 million) in a Series B financing round. The funding was led by China Life Equity Investment and included participation from existing investors Sherpa Healthcare Partners and GL Ventures, as well as new investors Shizhen Capital…
-
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
•
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt financing from SPD Silicon Valley Bank. The funding will support the development of IN10018 (BI853520), a focal adhesion kinase (FAK) inhibitor licensed from iPharma Ltd and Boehringer Ingelheim. Drug ProfileIN10018 is under clinical investigation in…
-
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
•
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round, bringing total investments in the firm to $195 million. The round follows a $35 million Series A led by OrbiMed and Creacion Ventures. Investors in the latest round include Boyu Capital, Sequoia China, OrbiMed, and…
-
Attec Completes Pre-Series A Financing with Sequoia China Backing Protein Degradation Tech
•
China-based biotech startup Attec has completed a pre-Series A financing round, with its protein degradation capabilities drawing investment from Sequoia China. The deal size was not disclosed. Company BackgroundFounded by Shanghai Fudan University professor Dr. Yu Ding, Attec specializes in drug discovery using protein degradation technology. The firm’s small-molecule glue…
-
Digital Precision Medicine Raises Hundreds of Millions in Series B Financing for Molecular Imaging Innovation
•
China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised hundreds of millions of renminbi in a Series B financing round. The round was co-led by Softbank China Venture Capital and Longmen Fund, with participation from Hangzhou Risheng Private Equity Fund Management Co., Ltd and…
-
Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development
•
Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has reportedly raised hundreds of millions of renminbi in a Series B financing round led by Weigao Holding’s fund. The proceeds will be used for product research and development and facilities construction. Company BackgroundFounded in 2016…
-
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
•
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership with Wuhan YZY Biopharma Co., Ltd, originally signed in September 2020. The deal granted Lummy exclusive priority sales rights to YZY Bio’s Y400, a bispecific antibody (BsAb) targeting VEGFA and ANG2, in Greater China. YZY…
-
Fermion Secures Series B Financing to Advance AI-Driven Drug Development
•
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B financing round led by iFLYTEK Venture Capital, Zhengxuan Capital, Panda Capital, and Challenjers Venture Capital. The funds will advance its core drug pipelines, including a Phase I clinical study for FZ002, a chronic pain candidate,…
-
Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform
•
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A financing round led by Qiming Venture Partners. The funds will support platform expansion, R&D, production, and market promotion. Company BackgroundFounded in 2012, Biotree conducts metabolomic and proteomic research on human, animal, plant, and microbial samples.…
-
Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots
•
Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion of a pre-Series C financing round of RMB100 million ($14.8 million). The round was led by Haichuang Group and Ningbo Qianwan Holding Group, with proceeds allocated to R&D, regulatory filings, and commercialization of orthopedic surgical…
-
Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline
•
China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture…
-
Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech
•
Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB 100 million ($14.9 million) in a Series B financing round co-led by Lake Bleu Capital and BioTrack Capital, with participation from 01VC and Long Hill Capital. The funds will support manufacturing, installation of its products,…
-
Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions
•
Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB 200 million ($29.8 million) in a Series B+ financing round led by Haier Capital. The round included participation from Xingtuo Capital and existing investors Innovation Works and Eastern Bell Capital. Proceeds will fuel market expansion,…
-
Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment
•
China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round led by Yuanbio Venture Capital, with existing investor Northern Light Venture Capital also participating. The proceeds will be used for clinical filings and global market promotion of…
-
GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics
•
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions” of renminbi in a recent financing round. The round was led by YF Capital and Gree Group, with contributions from Z & H Investment and Shanzhi Investment. Proceeds will be used to advance the commercialization…
-
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
•
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round. The funding was led by Insight Capital and Tenaya Capital, with participation from Highthink Med. The proceeds will be used for the upgrade of its…
-
ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion
•
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a financing round led by Legend Capital. Other investors included Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures, Apricot Capital, and SIP Oriza Seed Fund. The proceeds will be used for business expansion, new business…
